Question 1

What was the outcome of Eli Lilly's lawsuit against Strive Compounding Pharmacy?

Accepted Answer

On October 8, 2025, the United States District Court for the District of Delaware granted Strive's motion to dismiss without prejudice due to lack of personal jurisdiction.

Question 2

Why did Eli Lilly sue Strive Compounding Pharmacy?

Accepted Answer

Eli Lilly sued Strive for false and deceptive online advertising under Delaware's Uniform Deceptive Trade Practices Act and the Lanham Act, claiming Strive's marketing of customized tirzepatide medications was misleading.

Question 3

What specific marketing claims did Eli Lilly challenge in the lawsuit?

Accepted Answer

Eli Lilly challenged Strive's claims that its products were customized and specifically designed for individual needs, safer than Big Pharma products, and that Strive goes above and beyond regulatory standards.

Question 4

Why was the case dismissed for lack of personal jurisdiction?

Accepted Answer

The court found that Strive is an Arizona-based company with no physical presence in Delaware, and Eli Lilly failed to connect Strive's nationwide online advertising to Delaware specifically, despite Strive selling products through Delaware providers.

Question 5

How does Strive Compounding Pharmacy distribute its products?

Accepted Answer

Strive partners with local healthcare providers who prescribe GLP-1 medications, then ships the compounded drugs from its Arizona locations to providers and patients across the country, including Delaware.

Question 6

Did the court allow Eli Lilly to conduct jurisdictional discovery?

Accepted Answer

No, the court declined jurisdictional discovery because Eli Lilly failed to plead any facts connecting Strive's online advertisements specifically to Delaware, and unresolved disputes only related to general contacts with the state.

Question 7

Can Eli Lilly refile the lawsuit after the dismissal?

Accepted Answer

Yes, the dismissal was without prejudice, allowing Eli Lilly to either allege more jurisdictional facts connecting Strive's advertising to Delaware or sue Strive in Arizona where it is based.

Question 8

How much does it cost and how long does it take to bring a drug like tirzepatide to market?

Accepted Answer

According to the lawsuit, bringing the average drug to market takes more than ten years and $2.6 billion, and tirzepatide specifically took nearly a decade to invent and complete thirty-seven clinical trials for FDA approval.

Legal Reference

October 8, 2025